20 articles
Mayo Clinic tests whether 6 months of the SGLT2 inhibitor dapagliflozin can reduce exercise-induced cardiac pressure in preserved-ejection-fraction heart failure.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
70-person trial tested omega-3's effects on irisin and sirtuin-1, key proteins linked to metabolism and aging in diabetic patients.
A Phase 3 trial investigates whether the GLP-1 drug liraglutide can slow cognitive decline in T2DM patients at elevated Alzheimer's risk.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
Novel KH-1 supplement containing spermidine and probiotics tested for autophagy stimulation and glucose control in 42 prediabetic participants.
Study compares diabetes drug semaglutide to testosterone therapy for treating low hormone levels in men with diabetes and obesity.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Danish researchers studied how moderate exercise affects glucose regulation in diabetics versus healthy controls during fasted workouts.
Mediterranean diet, resistance training, and diabetes medication combined to combat sarcopenia and improve metabolic health in older adults.
UCSF study reveals how metformin and trimethoprim interfere with thiamine uptake, potentially affecting energy metabolism.
A Phase 2 trial tests whether selatogrel, a subcutaneous P2Y12 inhibitor, can rapidly block platelet aggregation in stable coronary artery disease patients.
411-person study shows digital insulin delivery system helps optimize glucose control through automated dose tracking and mobile integration.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
A Phase 1 trial examines if the triple-agonist GLP-1 drug retatrutide changes how the body processes the beta-blocker metoprolol.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
84-person study reveals how targeted nutrition counseling impacts blood sugar, weight, and heart health in diabetic patients.
Small study explores whether eating within 9-hour windows can improve blood sugar control and metabolic health in diabetic patients.
